Remdesivir (development code GS-5734) is an antiviral medication being studied during 2020 as a possible post-infection treatment for COVID-19 illness. Remdesivir is a nucleotide analog, specifically an adenosine analogue, which inserts into viral RNA chains, causing their premature termination.
Remdesivir is a prodrug form of the antiviral nucleoside analog GS-441524 (Item No. 30469). 1,2 Upon entry into cells, remdesivir is metabolized into the nucleotide triphosphate GS-441524. 1 Remdesivir is active against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome CoV (SARS-CoV) in infected primary human airway epithelial (HAE) cells (EC 50 s ...
Remdesivir, also known as GS-5734, inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h.
The NIH-sponsored trial will evaluate the safety and efficacy of the experimental antiviral drug remdesivir in hospitalized adults diagnosed with COVID-19. The first participant is an American who was repatriated after being quarantined on the Diamond Princess cruise ship in Japan.
Remdesivir is an investigational antiviral compound undergoing clinical trials in China, the United States, and the United Kingdom as a potential treatment for COVID-19. Remdesivir is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.